
Caribou Biosciences, Inc. (NASDAQ:CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.
A 100% complete response rate (6 of 6 patients) was observed as best response, with a 40% complete response rate (2 of 5 patients) at 6 months.